JP2015535832A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015535832A5 JP2015535832A5 JP2015533473A JP2015533473A JP2015535832A5 JP 2015535832 A5 JP2015535832 A5 JP 2015535832A5 JP 2015533473 A JP2015533473 A JP 2015533473A JP 2015533473 A JP2015533473 A JP 2015533473A JP 2015535832 A5 JP2015535832 A5 JP 2015535832A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- hal
- group
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- RVEOIAWOGIHTAH-FQEVSTJZSA-N CC(C)(CO)[C@H](C(NCCC(C(NCc(cc1)ccc1S(c1ccccc1)(=O)=O)=O)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCC(C(NCc(cc1)ccc1S(c1ccccc1)(=O)=O)=O)=O)=O)O RVEOIAWOGIHTAH-FQEVSTJZSA-N 0.000 description 1
- YONDKVCQXJTTAY-KRWDZBQOSA-N CC(C)(CO)[C@H](C(NCCN(CCCc1ccccc1)C(CF)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCN(CCCc1ccccc1)C(CF)=O)=O)O YONDKVCQXJTTAY-KRWDZBQOSA-N 0.000 description 1
- IAFNRNULFRXRMN-QFIPXVFZSA-N CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1-c1ccccc1)C(CCl)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1-c1ccccc1)C(CCl)=O)=O)O IAFNRNULFRXRMN-QFIPXVFZSA-N 0.000 description 1
- VHUCFYWMGFEVOC-INIZCTEOSA-N CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1Br)C(CCl)=O)=O)O Chemical compound CC(C)(CO)[C@H](C(NCCN(CCOc(cc1)ccc1Br)C(CCl)=O)=O)O VHUCFYWMGFEVOC-INIZCTEOSA-N 0.000 description 1
- YHHJEFYQKSJXMQ-INIZCTEOSA-N CCNC(Nc1ccc(CNC(C(CCNC([C@@H](C(C)(C)CO)O)=O)=O)=O)cc1)=O Chemical compound CCNC(Nc1ccc(CNC(C(CCNC([C@@H](C(C)(C)CO)O)=O)=O)=O)cc1)=O YHHJEFYQKSJXMQ-INIZCTEOSA-N 0.000 description 1
- -1 ammonium ions Chemical class 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185835.1 | 2012-09-25 | ||
| EP12185835 | 2012-09-25 | ||
| PCT/EP2013/002716 WO2014048547A1 (en) | 2012-09-25 | 2013-09-10 | Alpha hydroxy amides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015535832A JP2015535832A (ja) | 2015-12-17 |
| JP2015535832A5 true JP2015535832A5 (enExample) | 2016-12-22 |
Family
ID=46968027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533473A Ceased JP2015535832A (ja) | 2012-09-25 | 2013-09-10 | アルファヒドロキシアミド |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9585891B2 (enExample) |
| EP (1) | EP2900633A1 (enExample) |
| JP (1) | JP2015535832A (enExample) |
| CN (1) | CN104703965A (enExample) |
| AU (1) | AU2013324696B2 (enExample) |
| CA (1) | CA2885778A1 (enExample) |
| IL (1) | IL237841A0 (enExample) |
| WO (1) | WO2014048547A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| MY199894A (en) | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3215496B1 (en) | 2014-11-06 | 2019-01-02 | Radboud Universitair Medisch Centrum | Pantothenamide analogues |
| WO2016193844A1 (en) | 2015-05-29 | 2016-12-08 | Pfizer Inc. | Novel heterocyclic compounds as inhibitors of vanin-1 enzyme |
| US20180364233A1 (en) * | 2015-12-08 | 2018-12-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic sclerosis |
| MX2019000536A (es) * | 2016-07-14 | 2019-04-01 | Pfizer | Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1. |
| PE20210478A1 (es) | 2018-08-28 | 2021-03-11 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
| KR20210099093A (ko) | 2018-12-03 | 2021-08-11 | 베링거 인겔하임 인터내셔날 게엠베하 | 바닌 억제제로서의 헤테로방향족 화합물 |
| PE20211769A1 (es) * | 2018-12-03 | 2021-09-07 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
| PL3891142T3 (pl) | 2018-12-03 | 2023-01-02 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory waniny |
| CN111592472B (zh) | 2019-04-28 | 2022-10-21 | 纳莹(上海)生物科技有限公司 | 一种荧光染料及其制备方法和用途 |
| US20250009694A1 (en) * | 2021-11-02 | 2025-01-09 | Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for repairing intestinal mucosal |
| JP7506415B2 (ja) * | 2021-12-17 | 2024-06-26 | 学校法人大阪医科薬科大学 | Ｖａｎｉｎ－１阻害剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2692895A (en) * | 1950-08-23 | 1954-10-26 | Opfermann Adolf Christia Josef | Production of pantothenaldehyde and acetals thereof |
| JPS60248193A (ja) * | 1984-05-23 | 1985-12-07 | Dai Ichi Seiyaku Co Ltd | パンテテインの製造法 |
| US20040247524A1 (en) | 2003-06-05 | 2004-12-09 | Philippe Naquet | Method of treatment of an inflammatory disorder with a Vanin-1 antagonist |
| US7727738B2 (en) * | 2005-07-11 | 2010-06-01 | The Regents Of The University Of California | Methods for generating analogs of coenzyme A |
| WO2011152721A1 (en) | 2010-05-31 | 2011-12-08 | Umc St. Radboud | Derivatives of pantothenic acid and their use for the treatment of malaria |
| WO2012064632A1 (en) * | 2010-11-12 | 2012-05-18 | Wake Forest University Health Sciences | Methods of treating cancer and other disorders |
-
2013
- 2013-09-10 US US14/430,953 patent/US9585891B2/en not_active Expired - Fee Related
- 2013-09-10 CN CN201380049287.0A patent/CN104703965A/zh active Pending
- 2013-09-10 EP EP13759673.0A patent/EP2900633A1/en not_active Withdrawn
- 2013-09-10 JP JP2015533473A patent/JP2015535832A/ja not_active Ceased
- 2013-09-10 WO PCT/EP2013/002716 patent/WO2014048547A1/en not_active Ceased
- 2013-09-10 AU AU2013324696A patent/AU2013324696B2/en not_active Ceased
- 2013-09-10 CA CA2885778A patent/CA2885778A1/en not_active Abandoned
-
2015
- 2015-03-19 IL IL237841A patent/IL237841A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015535832A5 (enExample) | ||
| JP2009534405A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2013510825A5 (enExample) | ||
| JP2010540593A5 (enExample) | ||
| JP2013530179A5 (enExample) | ||
| JP2009532417A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2008515852A5 (enExample) | ||
| JP2016518385A5 (enExample) | ||
| JP2013544812A5 (enExample) | ||
| JP2016508505A5 (enExample) | ||
| JP2013518888A5 (enExample) | ||
| JP2008510828A5 (enExample) | ||
| JP2016518434A5 (enExample) | ||
| JP2016520618A5 (enExample) | ||
| JP2009534403A5 (enExample) | ||
| RU2011136250A (ru) | Низкомолекулярное полисульфатированное производное гиалуроновой кислоты и содержащее его лекарственное средство | |
| JP2015531773A5 (enExample) | ||
| JP2009504591A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| JP2015507636A5 (enExample) | ||
| JP2015535847A5 (enExample) | ||
| RU2314292C2 (ru) | Производные азетидина в качестве антагонистов ccr-3 рецептора |